549 related articles for article (PubMed ID: 19270670)
1. Bilski blundering biotech.
Simmons WJ
Nat Biotechnol; 2009 Mar; 27(3):245-8. PubMed ID: 19270670
[No Abstract] [Full Text] [Related]
2. The application of the patent laws to the drug approval process.
Coggio BD; Cerrito FD
Food Drug Law J; 1997; 52(4):345-55. PubMed ID: 10346669
[No Abstract] [Full Text] [Related]
3. Putting your best mode forward.
Tsao YR; Tabtiang RK
Nat Biotechnol; 2000 Oct; 18(10):1113-4. PubMed ID: 11017054
[No Abstract] [Full Text] [Related]
4. Obviousness, hindsight and perspective: the impact of KSR v. Teleflex on biotech and pharmaceutical patents.
Teitelbaum R; Cohen M
Nat Biotechnol; 2007 Oct; 25(10):1105-6. PubMed ID: 17921990
[No Abstract] [Full Text] [Related]
5. Biotech industry struggles with generics approval.
Knight J
Nature; 2004 Jun; 429(6992):588. PubMed ID: 15190316
[No Abstract] [Full Text] [Related]
6. Proposed changes to patent code loom over biotech industry.
Coombs A
Nat Biotechnol; 2007 Dec; 25(12):1333-4. PubMed ID: 18066010
[No Abstract] [Full Text] [Related]
7. Biotech patents-business as usual?
Lawrence S
Nat Biotechnol; 2008 Dec; 26(12):1326. PubMed ID: 19060861
[No Abstract] [Full Text] [Related]
8. Intellectual property. Decision on NFkappaB patent could have broad implications for biotech.
Garber K
Science; 2006 May; 312(5775):827. PubMed ID: 16690824
[No Abstract] [Full Text] [Related]
9. Walking the drug regulatory tightrope.
Dove A
Nat Biotechnol; 2003 May; 21(5):495-8. PubMed ID: 12721571
[No Abstract] [Full Text] [Related]
10. Enforcing pharmaceutical and biotech patent rights in China.
Zhang YP; Deng MM
Nat Biotechnol; 2008 Nov; 26(11):1235-40. PubMed ID: 18997760
[No Abstract] [Full Text] [Related]
11. Biotech in post-TRIPS India.
Ramani SV; Pradhan P; Ravi M
Nat Biotechnol; 2005 Jan; 23(1):18-9. PubMed ID: 15637608
[No Abstract] [Full Text] [Related]
12. Patent watch: EPO rejects reach through claims.
Nat Rev Drug Discov; 2010 Jan; 9(1):12. PubMed ID: 20043023
[No Abstract] [Full Text] [Related]
13. Reinventing an industry.
Mandavilli A
Nature; 2007 Jan; 445(7124):138-9. PubMed ID: 17215817
[No Abstract] [Full Text] [Related]
14. Patenting race.
Kahn J
Nat Biotechnol; 2006 Nov; 24(11):1349-51. PubMed ID: 17093476
[TBL] [Abstract][Full Text] [Related]
15. An audience with... Thomas Lönngren.
Lönngren T
Nat Rev Drug Discov; 2006 Mar; 5(3):182. PubMed ID: 16557656
[No Abstract] [Full Text] [Related]
16. Can open-source drug R&D repower pharmaceutical innovation?
Munos B
Clin Pharmacol Ther; 2010 May; 87(5):534-6. PubMed ID: 20407458
[TBL] [Abstract][Full Text] [Related]
17. "Ganske" threatens biotechnology patents worldwide.
Glaser V
Nat Biotechnol; 1997 Feb; 15(2):121. PubMed ID: 9035128
[No Abstract] [Full Text] [Related]
18. Patent fight sparks biological warfare in the drug industry.
Fortune; 2000 Jul; 142(3):40, 42. PubMed ID: 11066662
[No Abstract] [Full Text] [Related]
19. Overcoming the obstacles in the pharma/biotech industry: 2008 update.
Graul AI; Revel L; Rosa E; Cruces E
Drug News Perspect; 2009; 22(1):39-51. PubMed ID: 19209298
[TBL] [Abstract][Full Text] [Related]
20. [Similarity of biotechnology-derived drugs: regulatory framework and specificity].
Prugnaud JL
Ann Pharm Fr; 2008 Aug; 66(4):206-11. PubMed ID: 18847566
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
